Growth hormone treatment of early growth failure in toddlers with turner syndrome: A randomized, controlled, multicenter trial

Marsha L. Davenport; Brenda J. Crowe; Sharon H. Travers; Karen Rubin; Judith L. Ross; Patricia Y. Fechner; Daniel F. Gunther; Chunhua Liu; Mitchell E. Geffner; Kathryn Thrailkill; Carol Huseman; Anthony J. Zagar; Charmian A. Quigley

doi:10.1210/jc.2006-2874

Growth hormone treatment of early growth failure in toddlers with turner syndrome: A randomized, controlled, multicenter trial

Marsha L. Davenport, Brenda J. Crowe, Sharon H. Travers, Karen Rubin, Judith L. Ross, Patricia Y. Fechner, Daniel F. Gunther, Chunhua Liu, Mitchell E. Geffner, Kathryn Thrailkill, Carol Huseman, Anthony J. Zagar, Charmian A. Quigley

Research output: Contribution to journal › Article › peer-review

117 Scopus citations

Abstract

Context: Typically, growth failure in Turner syndrome (TS) begins prenatally, and height SD score (SDS) declines progressively from birth. Objective: This study aimed to determine whether GH treatment initiated before 4 yr of age in girls with TS could prevent subsequent growth failure. Secondary objectives were to identify factors associated with treatment response, to determine whether outcome could be predicted by a regression model using these factors, and to assess the safety of GH treatment in this young cohort. Design: This study was a prospective, randomized, controlled, openlabel, multicenter clinical trial (Toddler Turner Study, August 1999 to August 2003). Setting: The study was conducted at 11 U.S. pediatric endocrine centers. Subjects: Eighty-eight girls with TS, aged 9 months to 4 yr, were enrolled. Interventions: Interventions comprised recombinant GH (50 μg/kg·d; n = 45) or no treatment (n = 43) for 2 yr. Main Outcome Measure: The main outcome measure was baselineto-2-yr change in height SDS. Results: Short stature was evident at baseline (mean length/height SDS = -1.6 ± 1.0 at mean age 24.0 ± 12.1 months). Mean height SDS increased in the GH group from -1.4 ± 1.0 to -0.3 ± 1.1 (1.1 SDS gain), whereas it decreased in the control group from -1.8 ± 1.1 to -2.2 ± 1.2 (0.5 SDS decline), resulting in a 2-yr between-group difference of 1.6 ± 0.6 SDS (P < 0.0001). The baseline variable that correlated most strongly with 2-yr height gain was the difference between mid-parental height SDS and subjects' height SDS (r = 0.32; P = 0.04). Although attained height SDS at 2 yr could be predicted with good accuracy using baseline variables alone (R² = 0.81; P < 0.0001), prediction of 2-yr change in height SDS required inclusion of initial treatment response data (4-month or 1-yr height velocity) in the model (R² = 0.54; P < 0.0001). No new or unexpected safety signals associated with GH treatment were detected. Conclusion: Early GH treatment can correct growth failure and normalize height in infants and toddlers with TS.

Original language	English
Pages (from-to)	3406-3416
Number of pages	11
Journal	Journal of Clinical Endocrinology and Metabolism
Volume	92
Issue number	9
DOIs	https://doi.org/10.1210/jc.2006-2874
State	Published - Sep 2007

Bibliographical note

Funding Information:
This work was supported by Eli Lilly and Company (Indianapolis, IN). Portions of this work were conducted through and supported by the National Institutes of Health-funded General Clinical Research Center facilities at the University of Washington and Children's Hospital and Regional Medical Center (RR00037) and the University of North Carolina at Chapel Hill, North Carolina (RR00046). In compliance with the Uniform Requirements for Manuscripts, established by the International Committee of Medical Journal Editors, the sponsor of this study did not impose any impediment, directly or indirectly, on the publication of the study's results. The authors acknowledge the independent medical writing assistance provided by ProScribe Medical Communications ( www.proscribe.com.au ), funded by Eli Lilly and Company. ProScribe's services complied with international guidelines for Good Publication Practice.

Funding

This work was supported by Eli Lilly and Company (Indianapolis, IN). Portions of this work were conducted through and supported by the National Institutes of Health-funded General Clinical Research Center facilities at the University of Washington and Children's Hospital and Regional Medical Center (RR00037) and the University of North Carolina at Chapel Hill, North Carolina (RR00046). In compliance with the Uniform Requirements for Manuscripts, established by the International Committee of Medical Journal Editors, the sponsor of this study did not impose any impediment, directly or indirectly, on the publication of the study's results. The authors acknowledge the independent medical writing assistance provided by ProScribe Medical Communications ( www.proscribe.com.au ), funded by Eli Lilly and Company. ProScribe's services complied with international guidelines for Good Publication Practice.

Funders	Funder number
Children's Hospital and Regional Medical Center Seattle	RR00037
National Institutes of Health-funded
University of North Carolina and North Carolina State University	RR00046
ProScribe Medical Communications
Eli Lilly and Company
The George Washington University
University of North Carolina, Chapel Hill

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Endocrinology
Clinical Biochemistry
Biochemistry, medical

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1210/jc.2006-2874

Cite this

Davenport, M. L., Crowe, B. J., Travers, S. H., Rubin, K., Ross, J. L., Fechner, P. Y., Gunther, D. F., Liu, C., Geffner, M. E., Thrailkill, K., Huseman, C., Zagar, A. J., & Quigley, C. A. (2007). Growth hormone treatment of early growth failure in toddlers with turner syndrome: A randomized, controlled, multicenter trial. Journal of Clinical Endocrinology and Metabolism, 92(9), 3406-3416. https://doi.org/10.1210/jc.2006-2874

@article{d07f5aa82b21400ebdd008c8f2b3f349,

title = "Growth hormone treatment of early growth failure in toddlers with turner syndrome: A randomized, controlled, multicenter trial",

abstract = "Context: Typically, growth failure in Turner syndrome (TS) begins prenatally, and height SD score (SDS) declines progressively from birth. Objective: This study aimed to determine whether GH treatment initiated before 4 yr of age in girls with TS could prevent subsequent growth failure. Secondary objectives were to identify factors associated with treatment response, to determine whether outcome could be predicted by a regression model using these factors, and to assess the safety of GH treatment in this young cohort. Design: This study was a prospective, randomized, controlled, openlabel, multicenter clinical trial (Toddler Turner Study, August 1999 to August 2003). Setting: The study was conducted at 11 U.S. pediatric endocrine centers. Subjects: Eighty-eight girls with TS, aged 9 months to 4 yr, were enrolled. Interventions: Interventions comprised recombinant GH (50 μg/kg·d; n = 45) or no treatment (n = 43) for 2 yr. Main Outcome Measure: The main outcome measure was baselineto-2-yr change in height SDS. Results: Short stature was evident at baseline (mean length/height SDS = -1.6 ± 1.0 at mean age 24.0 ± 12.1 months). Mean height SDS increased in the GH group from -1.4 ± 1.0 to -0.3 ± 1.1 (1.1 SDS gain), whereas it decreased in the control group from -1.8 ± 1.1 to -2.2 ± 1.2 (0.5 SDS decline), resulting in a 2-yr between-group difference of 1.6 ± 0.6 SDS (P < 0.0001). The baseline variable that correlated most strongly with 2-yr height gain was the difference between mid-parental height SDS and subjects' height SDS (r = 0.32; P = 0.04). Although attained height SDS at 2 yr could be predicted with good accuracy using baseline variables alone (R2 = 0.81; P < 0.0001), prediction of 2-yr change in height SDS required inclusion of initial treatment response data (4-month or 1-yr height velocity) in the model (R2 = 0.54; P < 0.0001). No new or unexpected safety signals associated with GH treatment were detected. Conclusion: Early GH treatment can correct growth failure and normalize height in infants and toddlers with TS.",

author = "Davenport, {Marsha L.} and Crowe, {Brenda J.} and Travers, {Sharon H.} and Karen Rubin and Ross, {Judith L.} and Fechner, {Patricia Y.} and Gunther, {Daniel F.} and Chunhua Liu and Geffner, {Mitchell E.} and Kathryn Thrailkill and Carol Huseman and Zagar, {Anthony J.} and Quigley, {Charmian A.}",

note = "Funding Information: This work was supported by Eli Lilly and Company (Indianapolis, IN). Portions of this work were conducted through and supported by the National Institutes of Health-funded General Clinical Research Center facilities at the University of Washington and Children's Hospital and Regional Medical Center (RR00037) and the University of North Carolina at Chapel Hill, North Carolina (RR00046). In compliance with the Uniform Requirements for Manuscripts, established by the International Committee of Medical Journal Editors, the sponsor of this study did not impose any impediment, directly or indirectly, on the publication of the study's results. The authors acknowledge the independent medical writing assistance provided by ProScribe Medical Communications ( www.proscribe.com.au ), funded by Eli Lilly and Company. ProScribe's services complied with international guidelines for Good Publication Practice. ",

year = "2007",

month = sep,

doi = "10.1210/jc.2006-2874",

language = "English",

volume = "92",

pages = "3406--3416",

number = "9",

}

Davenport, ML, Crowe, BJ, Travers, SH, Rubin, K, Ross, JL, Fechner, PY, Gunther, DF, Liu, C, Geffner, ME, Thrailkill, K, Huseman, C, Zagar, AJ & Quigley, CA 2007, 'Growth hormone treatment of early growth failure in toddlers with turner syndrome: A randomized, controlled, multicenter trial', Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 9, pp. 3406-3416. https://doi.org/10.1210/jc.2006-2874

TY - JOUR

T1 - Growth hormone treatment of early growth failure in toddlers with turner syndrome

T2 - A randomized, controlled, multicenter trial

AU - Davenport, Marsha L.

AU - Crowe, Brenda J.

AU - Travers, Sharon H.

AU - Rubin, Karen

AU - Ross, Judith L.

AU - Fechner, Patricia Y.

AU - Gunther, Daniel F.

AU - Liu, Chunhua

AU - Geffner, Mitchell E.

AU - Thrailkill, Kathryn

AU - Huseman, Carol

AU - Zagar, Anthony J.

AU - Quigley, Charmian A.

N1 - Funding Information: This work was supported by Eli Lilly and Company (Indianapolis, IN). Portions of this work were conducted through and supported by the National Institutes of Health-funded General Clinical Research Center facilities at the University of Washington and Children's Hospital and Regional Medical Center (RR00037) and the University of North Carolina at Chapel Hill, North Carolina (RR00046). In compliance with the Uniform Requirements for Manuscripts, established by the International Committee of Medical Journal Editors, the sponsor of this study did not impose any impediment, directly or indirectly, on the publication of the study's results. The authors acknowledge the independent medical writing assistance provided by ProScribe Medical Communications ( www.proscribe.com.au ), funded by Eli Lilly and Company. ProScribe's services complied with international guidelines for Good Publication Practice.

PY - 2007/9

Y1 - 2007/9

N2 - Context: Typically, growth failure in Turner syndrome (TS) begins prenatally, and height SD score (SDS) declines progressively from birth. Objective: This study aimed to determine whether GH treatment initiated before 4 yr of age in girls with TS could prevent subsequent growth failure. Secondary objectives were to identify factors associated with treatment response, to determine whether outcome could be predicted by a regression model using these factors, and to assess the safety of GH treatment in this young cohort. Design: This study was a prospective, randomized, controlled, openlabel, multicenter clinical trial (Toddler Turner Study, August 1999 to August 2003). Setting: The study was conducted at 11 U.S. pediatric endocrine centers. Subjects: Eighty-eight girls with TS, aged 9 months to 4 yr, were enrolled. Interventions: Interventions comprised recombinant GH (50 μg/kg·d; n = 45) or no treatment (n = 43) for 2 yr. Main Outcome Measure: The main outcome measure was baselineto-2-yr change in height SDS. Results: Short stature was evident at baseline (mean length/height SDS = -1.6 ± 1.0 at mean age 24.0 ± 12.1 months). Mean height SDS increased in the GH group from -1.4 ± 1.0 to -0.3 ± 1.1 (1.1 SDS gain), whereas it decreased in the control group from -1.8 ± 1.1 to -2.2 ± 1.2 (0.5 SDS decline), resulting in a 2-yr between-group difference of 1.6 ± 0.6 SDS (P < 0.0001). The baseline variable that correlated most strongly with 2-yr height gain was the difference between mid-parental height SDS and subjects' height SDS (r = 0.32; P = 0.04). Although attained height SDS at 2 yr could be predicted with good accuracy using baseline variables alone (R2 = 0.81; P < 0.0001), prediction of 2-yr change in height SDS required inclusion of initial treatment response data (4-month or 1-yr height velocity) in the model (R2 = 0.54; P < 0.0001). No new or unexpected safety signals associated with GH treatment were detected. Conclusion: Early GH treatment can correct growth failure and normalize height in infants and toddlers with TS.

AB - Context: Typically, growth failure in Turner syndrome (TS) begins prenatally, and height SD score (SDS) declines progressively from birth. Objective: This study aimed to determine whether GH treatment initiated before 4 yr of age in girls with TS could prevent subsequent growth failure. Secondary objectives were to identify factors associated with treatment response, to determine whether outcome could be predicted by a regression model using these factors, and to assess the safety of GH treatment in this young cohort. Design: This study was a prospective, randomized, controlled, openlabel, multicenter clinical trial (Toddler Turner Study, August 1999 to August 2003). Setting: The study was conducted at 11 U.S. pediatric endocrine centers. Subjects: Eighty-eight girls with TS, aged 9 months to 4 yr, were enrolled. Interventions: Interventions comprised recombinant GH (50 μg/kg·d; n = 45) or no treatment (n = 43) for 2 yr. Main Outcome Measure: The main outcome measure was baselineto-2-yr change in height SDS. Results: Short stature was evident at baseline (mean length/height SDS = -1.6 ± 1.0 at mean age 24.0 ± 12.1 months). Mean height SDS increased in the GH group from -1.4 ± 1.0 to -0.3 ± 1.1 (1.1 SDS gain), whereas it decreased in the control group from -1.8 ± 1.1 to -2.2 ± 1.2 (0.5 SDS decline), resulting in a 2-yr between-group difference of 1.6 ± 0.6 SDS (P < 0.0001). The baseline variable that correlated most strongly with 2-yr height gain was the difference between mid-parental height SDS and subjects' height SDS (r = 0.32; P = 0.04). Although attained height SDS at 2 yr could be predicted with good accuracy using baseline variables alone (R2 = 0.81; P < 0.0001), prediction of 2-yr change in height SDS required inclusion of initial treatment response data (4-month or 1-yr height velocity) in the model (R2 = 0.54; P < 0.0001). No new or unexpected safety signals associated with GH treatment were detected. Conclusion: Early GH treatment can correct growth failure and normalize height in infants and toddlers with TS.

UR - http://www.scopus.com/inward/record.url?scp=34548804590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548804590&partnerID=8YFLogxK

U2 - 10.1210/jc.2006-2874

DO - 10.1210/jc.2006-2874

M3 - Article

C2 - 17595258

AN - SCOPUS:34548804590

SN - 0021-972X

VL - 92

SP - 3406

EP - 3416

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

IS - 9

ER -

Growth hormone treatment of early growth failure in toddlers with turner syndrome: A randomized, controlled, multicenter trial

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this